Tim Schmid

New Capabilities

As of May 2026: Leading J&J's medical device growth strategy, including vision

For a decade, patients choosing premium lenses during cataract surgery have faced a trade-off: better vision range, but dimmer, lower-contrast sight—especially in low light. On March 12, 2026, the FDA approved Johnson & Johnson's TECNIS PureSee, the first extended depth of focus lens cleared in the U.S. without a contrast sensitivity warning.

Updated May 30